MedPath

Study on QOL improvement with the glucide diet which enhanced protein and EPA in advanced colorectal cancer and breast cancer for stage IV

Phase 1
Conditions
colorectal cancer, breast cancer
Registration Number
JPRN-UMIN000029527
Lead Sponsor
Tama-Nanbu Regional Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation. Department of Surgery
Brief Summary

A 3-month combination of the modified MCT ketogenic diet and chemotherapy was safe for stage IV cancer patients and allowed them to maintain quality of life. We believe that tumor reduction was associated with blood ketone body level.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Diabetic patient Cachexy patient

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The evaluation is every month after a glucide diet start. Blood sugar level, blood ketone body density, the weight, albumin level, renal function (BUN, Cr), liver function (GOT, GPT), QOL score)
Secondary Outcome Measures
NameTimeMethod
The evaluation is three month after a glucide diet start. The RECIST evaluation by the examination for CT. Change of the tumor marker
© Copyright 2025. All Rights Reserved by MedPath